Next Article in Journal
Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON
Next Article in Special Issue
Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy
Previous Article in Journal
The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
Previous Article in Special Issue
Myc, Oncogenic Protein Translation, and the Role of Polyamines
Open AccessArticle

Knocking out Ornithine Decarboxylase Antizyme 1 (OAZ1) Improves Recombinant Protein Expression in the HEK293 Cell Line

1
Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
2
Department of Chemistry and Biochemistry, George Mason University, Fairfax, VA 22030, USA
*
Author to whom correspondence should be addressed.
Med. Sci. 2018, 6(2), 48; https://doi.org/10.3390/medsci6020048
Received: 2 April 2018 / Revised: 30 May 2018 / Accepted: 1 June 2018 / Published: 8 June 2018
(This article belongs to the Special Issue Polyamine Metabolism in Disease and Polyamine-Targeted Therapies)
Creating efficient cell lines is a priority for the biopharmaceutical industry, which produces biologicals for various uses. A recent approach to achieving this goal is the use of non-coding RNAs, microRNA (miRNA) and small interfering RNA (siRNA), to identify key genes that can potentially improve production or growth. The ornithine decarboxylase antizyme 1 (OAZ1) gene, a negative regulator of polyamine biosynthesis, was identified in a genome-wide siRNA screen as a potential engineering target, because its knock down by siRNA increased recombinant protein expression from human embryonic kidney 293 (HEK293) cells by two-fold. To investigate this further, the OAZ1 gene in HEK293 cells was knocked out using CRISPR genome editing. The OAZ1 knockout cell lines displayed up to four-fold higher expression of both stably and transiently expressed proteins, with comparable growth and metabolic activity to the parental cell line; and an approximately three-fold increase in intracellular polyamine content. The results indicate that genetic inactivation of OAZ1 in HEK293 cells is an effective strategy to improve recombinant protein expression in HEK293 cells. View Full-Text
Keywords: protein expression; antizyme 1; ornithine decarboxylase; CRISPR; human embryonic kidney 293 (HEK293) protein expression; antizyme 1; ornithine decarboxylase; CRISPR; human embryonic kidney 293 (HEK293)
Show Figures

Figure 1

MDPI and ACS Style

Abaandou, L.; Shiloach, J. Knocking out Ornithine Decarboxylase Antizyme 1 (OAZ1) Improves Recombinant Protein Expression in the HEK293 Cell Line. Med. Sci. 2018, 6, 48.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop